Etretinate Treatment of the Nevoid Basal Cell Carcinoma Syndrome

Abstract
A patient suffering from the nevoid basal cell carcinoma syndrome, in whom various surgical and conservative treatment modalities had been tried previously, was placed on oral etretinate therapy. A therapeutic effect of the etretinate on existing basal cell carcinomas and a prophylactic effect in inhibiting new tumor formation were well demonstrated during the T3‐montri period of treatment.